scholarly journals FEATURES OF THE FUNCTIONAL STATE OF MUSCLE TISSUE IN ELDERLY PATIENTS WITH URGENT SURGICAL PATHOLOGY

World Science ◽  
2021 ◽  
Author(s):  
Rasenko Andrii
Keyword(s):  
Type 2 Diabetes ◽  
Elderly Patients ◽  
Muscle Tissue ◽  
Metabolic Disorders ◽  
Surgical Pathology ◽  
Important Criterion ◽  
Functional Disorders ◽  
And Function ◽  
Disorders Of Lipid Metabolism

Sarcopenia is an important factor in the occurrence of complications in elderly patients with urgent surgical pathology. Decreased muscle strength and function is an important criterion for impaired early activation of such patients, which increases the number of complications and length of stay in the clinic. Identification of functional disorders of muscle tissue, as well as other metabolic disorders, such as type 2 diabetes, disorders of lipid metabolism, is important for the appointment of an adequate complex of intensive care. Prescribing levocarnitine and D-fructose-1,6-diphosphate sodium salt of hydrate is an important part of the treatment program in such patients.

Abstract #295 GLP-1 Receptor Agonists and Death From Any Cause in Elderly Patients with Type 2 Diabetes Mellitus: A Post-Hoc Analysis

2018 ◽  
Vol 24 ◽  
pp. 80-81
Author(s):  
Konstantinos Toulis ◽  
Krishna Gokhale ◽  
G. Neil Thomas ◽  
Wasim Hanif ◽  
Krishnarajah Nirantharakumar ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Elderly Patients ◽  
Post Hoc Analysis ◽  
Receptor Agonists ◽  
Post Hoc

1172-P: GLUT4-Overexpressing Engineered Muscle Tissue Implants as a Potential Novel Therapy for Type 2 Diabetes: Lessons from Diabetic Mice

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1172-P
Author(s):  
MARGARITA BECKERMAN ◽  
EDDY KARNIELI ◽  
CHAVA HAREL ◽  
AMIRA KLIP ◽  
PHILIP J. BILAN ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Muscle Tissue ◽  
Diabetic Mice ◽  
Novel Therapy

771-P: Protein Intake at Breakfast Contributes to Maintenance of Skeletal Muscle Mass in Japanese Elderly Patients with Type 2 Diabetes

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 771-P
Author(s):  
SODAI KUBOTA ◽  
HITOSHI KUWATA ◽  
SAKI OKAMOTO ◽  
DAISUKE YABE ◽  
KENTA MUROTANI ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Skeletal Muscle ◽  
Elderly Patients ◽  
Muscle Mass ◽  
Protein Intake ◽  
Skeletal Muscle Mass ◽  
P Protein ◽  
Japanese Elderly

2114-P: Use of Visceral Fat Area Measurement for Evaluating Obesity in Elderly Patients with Type 2 Diabetes

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 2114-P
Author(s):  
TAKUYA MINAMIZUKA ◽  
YUKARI MAEDA ◽  
MASAYA KOSHIZAKA ◽  
TAKAHIRO ISHIKAWA ◽  
YOSHIRO MAEZAWA ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Elderly Patients ◽  
Visceral Fat ◽  
Area Measurement ◽  
Visceral Fat Area

2306-PUB: Long-Term Effect of Liraglutide on the Prevention of Progression of Diabetic Nephropathy in Elderly Patients with Type 2 Diabetes

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 2306-PUB
Author(s):  
MAMI YOSHIDA ◽  
AI YOSHIDA ◽  
ERIKO OH ◽  
NAOMUNE YAMAMOTO ◽  
EUN SASAKI ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Diabetic Nephropathy ◽  
Elderly Patients ◽  
Term Effect ◽  
Long Term Effect

scholarly journals The Relationship between the Gut Microbiome and Metformin as a Key for Treating Type 2 Diabetes Mellitus

2021 ◽  
Vol 22 (7) ◽  
pp. 3566
Author(s):  
Chae Bin Lee ◽  
Soon Uk Chae ◽  
Seong Jun Jo ◽  
Ui Min Jerng ◽  
Soo Kyung Bae
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glucose Metabolism ◽  
Gut Microbiome ◽  
Metabolic Disorders ◽  
Current Knowledge ◽  
Potential Target ◽  
The Relationship

Metformin is the first-line pharmacotherapy for treating type 2 diabetes mellitus (T2DM); however, its mechanism of modulating glucose metabolism is elusive. Recent advances have identified the gut as a potential target of metformin. As patients with metabolic disorders exhibit dysbiosis, the gut microbiome has garnered interest as a potential target for metabolic disease. Henceforth, studies have focused on unraveling the relationship of metabolic disorders with the human gut microbiome. According to various metagenome studies, gut dysbiosis is evident in T2DM patients. Besides this, alterations in the gut microbiome were also observed in the metformin-treated T2DM patients compared to the non-treated T2DM patients. Thus, several studies on rodents have suggested potential mechanisms interacting with the gut microbiome, including regulation of glucose metabolism, an increase in short-chain fatty acids, strengthening intestinal permeability against lipopolysaccharides, modulating the immune response, and interaction with bile acids. Furthermore, human studies have demonstrated evidence substantiating the hypotheses based on rodent studies. This review discusses the current knowledge of how metformin modulates T2DM with respect to the gut microbiome and discusses the prospect of harnessing this mechanism in treating T2DM.

Sign in / Sign up

Export Citation Format

Share Document